Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process–A systematic review. (17th January 2020)

• Record Type: Journal Article
• Authors: Guerrisi, Antonino; Loi, Emiliano; Ungania, Sara; Russillo, Michelangelo; Bruzzaniti, Vicente; Elia, Fulvia; Desiderio, Flora; Marconi, Raffaella; Solivetti, Francesco Maria; Strigari, Lidia
• Is Part Of: Cancer medicine. Volume 9:Number 5(2020)
• Page Start: 1603
• Page End: 1612
• Publication Date: 2020-01-17
• Subjects: cutaneous melanoma -- immunotherapy -- precision medicine -- radiomics -- texture analysis; 616.994005
• DOI: 10.1002/cam4.2709
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Advanced malignant melanoma represents a public health matter due to its rising incidence and aggressiveness. Novel therapies such as immunotherapy are showing promising results with improved progression free and overall survival in melanoma patients. However, novel targeted and immunotherapies could generate atypical patterns of response which are nowadays a big challenge since imaging criteria (ie Recist 1.1) have not been proven to be always reliable to assess response. Radiomics and in particular texture analysis (TA) represent new quantitative methodologies which could reduce the impact of these limitations providing most robust data in support of clinical decision process. The aim of this paper was to review the state of the art of radiomics/TA when it is applied to the imaging of metastatic melanoma patients. Abstract : Novel cancer therapies are showing promising results with improved progression free and overall survival in patients with advanced melanoma. Radiomics represents new emerging quantitative methodologies that provide most robust data to support clinical decision in particular when atypical treatment response is present in these patients. The aim of this paper was to review the state of the art of radiomics when it is applied to the imaging of malignant melanoma patients.